Zusammenfassung
Aufgrund der Fortschritte bei der Chemotherapie und vor dem Hintergrund der Nebenwirkungen ist die beim Ovarialkarzinom ebenfalls effektive Strahlentherapie in den letzten Jahren weitgehend verlassen worden. Dies schließt die intraperitoneale Therapie mit Radionukliden (vor allem Radiophosphor) ein. Als Gründe werden die geringe Reichweite der Strahlung im Gewebe (— mm) sowie die nur schlecht berechenbare und oftmals inadaquate Dosisverteilung angeführt [19). Im Folgenden soll versucht werden, zu überprüfen, ob und wenn ja, welcher Stellenwert der intraperitonealen Behandlung mit Radiophosphor (32p) in der Behandlung des Ovarialkarzinoms zukommt.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Bakri YN, Given FT (1984) Radioactivity in blood and urine following intraperitoneal instillation of chromic phosphate in patients with and without ascites. Am J Obstet Gynecol 150:184–187
Bakri YN, Given FT, Peeples WJ, Frazier AB (1985) Complications from intraperitoneal radioactive phosphorus in ovarian malignancies. Gynecol Oncol 21:294–299
Bolis G, Colombo N, Pecorelli S et al. (GICOG) (1995) Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol 6:887–893
Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ (1998) Field cancerization: why late “recurrent” ovarian cancer ist not recurrent. Am J Obstet Gynecol 178:641–649
Card RY, Cole DR, Henschke UK (1960) Summary of ten years of the use of radioactive colloids in intracavitary therapy. J Nucl Med 1:195–198
Hilaris BS, Clark DGC (1971) The value of postoperative intraperitoneal injection of radiocolloids in early cancer of the ovary. Am J Roentgenol 122: 749–754
McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6
Ozols RF, Garvin AJ, Costa J, Simon RM, Young RC (1980) Advanced ovarian cancer. Correlation of histologic grade with response to chemotherapy and survival. Cancer 45:572–581
Peters WA, Smith MR, Cain JM, Lee RB, Yon JL (1992) Intraperitoneal P-32 ist not an effective consolidation therapy after a negative secondlook laparotomy for epithelial carcinoma of the ovary. Gynecol Oncol 47:146 -149
Pezner RP, Stevens KR, Tong D, Allen CV (1978) Limited epithelial carcinoma of the ovary treated with curative intent by the intraperitoneal instillation of radiocolloids. Cancer 42:2563–2571
Piver MS, Barlow JJ, Lele SB, Bakshi S, Parthasarathy KL, Bender MA (1982) Intraperitoneal chromic phosphate in peritoneoscopically confirmed stage I ovarian adenocarcinoma. Am J Obstet Gynecol 144:836–840
Potter ME, Partidge EE, Shingleton HM, Soong SJ, Kim RY, Hatch KD, Austin JM (1989) Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits. Gynecol Oncol 32:314–318
Rauterkus RP (1998) Ergebnisse bei 1086 Patientinnen mit primären Ovarialkarzinomen, die von 1970-1993 am Zentrum für Frauenheilkunde und Geburtshilfe Giessen behandelt wurden, unter besonderer Berücksichtigung der intraperitonealen Radionuklidinstillation. Inauguraldissertation Gießen 1998
Rogers L, Varia M, Halle J, Freddo J, O’Keefe T, Fowler W(1990) 32P following second look laparotomy for epithelial ovarian cancer (abstr). Int J Radiat Oncol Biol Phys 19[Suppl 1]:167–168
Rosenshein NB, Leichner PK, Vogelsang G (1979) Radiocolloids in the treatment of ovarian cancer. Obstet Gynecol Surv 34:708–720
Soper JT, Wilkinson RH, Bandy LC, Clarke-Pearson DL, Creasman WT (1987) Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol 156:1153–1158
Spanos WJ Jr, Day T Jr, Jose B, Paris K, Lindberg RD (1994) Use of P 32 in stage III epithelial carcinoma of the ovary. Gynecol Oncol 54:35–39
Spencer TR Jr, Marks RD, Fenn JO, Jenrette JM, Lutz MH (1989) Intraperitoneal P 32 after negative second look laparotomy in ovarian carcinoma. Cancer 63:2434–2437
Tumorzentrum München (1998) Maligne Ovarialtumoren- Empfehlungen zur Diagnostik, Therapie und Nachsorge
Vahrson HW, Nitz U, Bender HG (1997) Malignancies of the ovaries. In: Vahrson HW (ed) Radiation oncology of gynecological cancers. Springer, Berlin Heidelberg New York
Varia M, Rosenman J, Venkatraman S et al. (1988) Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer. Cancer 61:919–927
Vergote IB,Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjorstad KE, Trope CG (1992) Randomized trial comparing cisplatin with radioactive phosphorus or whole abdomen irradiation as adjuvant treatment of ovarian cencer. Cancer 69:741–749
Vergote IB, Winderen M, De Vos LN, Trope CG (1993) Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second look laparotomy. Cancer 71:2250–2260
Walton LA, Yadusky A, Rubinstein L (1991) Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications. Int J Radiat Oncol Biol Phys 20:939–944
Young RC, Walton LA, Ellenberg SS et al. (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer - results of two prospective randomized trials. N Engl J Med 322:1021–1027
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Münstedt, K., Kullmer, U. (2000). Hat die Radiophosphortherapie in der Behandlung des Ovarialkarzinoms noch einen Platz?. In: Künzel, W., Kirschbaum, M. (eds) Gießener Gynäkologische Fortbildung 1999. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59634-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-59634-6_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-65939-6
Online ISBN: 978-3-642-59634-6
eBook Packages: Springer Book Archive